Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity

Journal of Immunology

Volumn 160, Issue 12, 1998, Pages 5781-5789

  Matsumoto, Goichi ^b   Nghiem, Mai P ^a   Nozaki, Naohito ^b   Schmits, Rudolf ^a   Penninger, Josef M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; HERMES ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; DRUG RECEPTOR BINDING; EFFECTOR CELL; GENE MUTATION; LIGAND BINDING; LYMPHOKINE ACTIVATED KILLER CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TARGET CELL;

ANIMALS; ANTIGENS, CD44; CELL ADHESION; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HYALURONIC ACID; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIGANDS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MEMBRANE GLYCOPROTEINS; MICE; PORE FORMING CYTOTOXIC PROTEINS; SPLEEN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032526630     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Leibson, P. J. 1997. Signal transaction during natural killer cell activation: inside the mind of a killer. Immunity 6:656.
2. Trichieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
3. Bancroft, G. J. 1993. The role of natural killer cells in innate resistance to infection. Curr. Opin. Immunol. 5:503.
4. Das, B., M. O. Mondragon, S.-Z. Tao. and A. J. Norin. 1997. Preferential interaction of a novel tumor surface protein (p38.5) with natural killer cells. J. Exp. Med. 185:1735.
5. Grimm, E. A., R. J. Robb, J. A. Roth, L. M. Neckers, L. B. Rachman, D. J. Wilson, and S. A. Rosenberg. 1983. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral lymphocytes into lymphokine-activated killer cells. J. Exp. Med. 158: 1356.
6. Rosenstein, Y., I. Yron, Y. Kaufman, and S. A. Rosenberg. 1984. Lymphokine-activated killer cells: lysis of fresh syngenic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 44: 1946.
7. Kagi, D., F. Vignaux, B. Lederman, K. Burki, V. Depractera, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathway as major mechanisms of T cell-mediated cytotoxicity. Science 265:524.
8. Singer, S. J. 1992. Intercellular communication and cell-cell adhesion. Science 255:1671.
9. Zinkernagel, R. M., M. F. Bachmann, T. M. Kundig, S. Oehen, H. Pircher, and H. Hengartner. 1996. On immunological memory. Annu. Rev. Immunol. 14:333.
10. Dustin, M. L., and T. A. Springer. 1989. T-cell receptor crosslinking transiently stimulates adhesiveness through LFA-1. Nature 341:619.
11. Gumperz, J. E., and P. Parham. 1995. The enigma of the natural killer cell. Nature 378:245.
12. Schmits, R., T. M. Kunding, D. M. Baker, G. S. Shumaker, J. J. L. Simard, G. Duncan, A. Wakeman, A. Shahnian, A. van der Heiden, M. F. Bachmann, P. S. Ohashi, and T. W. Mak. 1996. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J. Exp. Med. 183: 1415.
13. Schmits, R., J. Filmus, N. Gerwin, G. Senaldi, F. Kiefer, T. Kundig, A. Wakeham. A. Shahinian, C. Catzavelos, J. Rak, C. Furlonger, A. Zakarian, J. J. L. Simard, P. S. Ohashi, C. J. Paige, J. C. Gutierrez-Ramos, and T. W. Mak. 1997. CD44 regulates hematopoietic progenitor distribution, granuloma formation and tumorigenicity. Blood 90:2217.
14. Vujanovic, N. L., R. B. Herberman, A. A. Maghazachi, and J. C. Hiserodt. 1988. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J. Exp. Med. 167:15.
15. Becker, J. C., R. Dummer, A. A. Hartmann, G. Burg, and R. E. Schmidt. 1991. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-γ and tumor necrosis faclor-α. J. Immunol. 147:4398.
16. Shier, P., G. Otulakowski, K. Nugo, J. Pankos, E. Chourmouzis, L. Christjansen, C. Y. Lau, and W. P. Fung-Leung. 1996. Impaired immune responses toward alloantigens and tumor cells hut normal thymic selection in mice deficient in the β2 integrin leukocyte function-associated antigen-1. J. Immunol. 157:5375.
17. Lee, R. K., J. Spielman, D. Y. Zaho, K. J. Oslen, and E. R. Padock. 1996. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 157:1919.
18. Zeng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenard. 1995. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 377:348.
19. Saunton, D. E., M. L. Dustin, and T. A. Springer. 1989. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339: 61.
20. Aruffo, A., I. Stamenkovic, M. Melnic, C. B. Underbill, and B. Seed. 1990. CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303.
21. Vanky, F., P. Wang, M. Patarroyo, and E. Klein. 1990. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol. Immunother. 31:19.
22. Krensky, A. M., S. J. Mentzer, C. Clayberger, D. C. Anderson, F. C. Schmalstieg, S. J. Burkoff, and T. A. Springer. 1985. Heritable lymphocyte function-associated antigen-1 deficiency: abnormalities of cytotoxicity and proliferation associated with abnormal expression of LFA-1. J. Immunol. 135:3102.
23. Grimm, E. A., A. Mazumder, H. Z. Zang, and S. A. Rosenberg. 1982, Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823.
24. Rosenberg, S. A., and M. T. Lotze, 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4:681.
25. Phillips, J. H., and L. L. Lanier. 1986. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 164:814.
26. Liu, C. C., C. M. Walsh, N. Eto, R. Clark, and J. D. Young. 1995. Morphological and functional characterization of perforin-deficient lymphokine-activated killer cells. J. Immunol. 155:602.
27. Krensky, A. M., F. Sanchez-Madrid, E. Robbins, J. A. Nagy, T. A. Springer, and S. J. Burakoff. 1983. The functional significance, distribution, and structure of LFA-1. LFA-2, and LFA-3: cell surface antigen associated with CTL-target interactions. J. Immunol. 131:611.
28. Hildreth, J. E. K., F. M. Gotch, P. D. K. Hildreth, and A. J. McMichael. 1983. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur. J. Immunol. 13:202.
29. Chen, B. P., M. Malkovsky, J. A. Hank, and P. M. Sondel. 1987. Nonrestricted cytotoxicity mediated interleukin 2-expressed leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (Mo Ab) but potentiated by anti-CD 3 MoAb. Cell. Immunol. 110:282.
30. Krensky, A. M., E. Robbins, T. A. Springer, and S. J. Burrakoff. 1984. LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J. Immunol. 132:2180.
31. Lesley, J., R. Hyman, and P. W. Kincade. 1993. CD44 and its interaction with ECM. Adv. Immunol. 54:271.
32. Hynes, B. F., M. J. Telen, L. P. Hele, and S. M. Denning, 1989. CD44: a molecule involved in leukocyte adherence and T cell activation. Immunol. Today 10:423.
33. MEL-14. Proc. Natl. Acad. Sci. USA 88:7877.
34. Galandrini, R., R. D. Maria, M. Piccoli, and A. Santoni. 1994. CD44 triggering enhances human NK cell cytotoxic function. J. Immunol. 153:4339.
35. Underhil, C. 1992. CD44: the hyaluronan receptor. J. Cell Sci. 103:293.
36. Wayner, E. A., and W. G. Carter. 1987. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique α and common β subunits. J. Cell Biol. 105:1873.
37. Naujokas, M. F., M. Morin, M. S. Anderson, M. Peterson, and J. Miller. 1993. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74:257.
38. Toyama-Sorimachi, N., H. Sorimachi, Y. Tobita, F. Kitamura, H. Yagita, K. Suzuki, and M. Miyasaka. 1995. A novel ligand for CD44 is serglysin, a hematopoietic cell lineage-specific proteoglycan. J. Biol. Chem. 270:7437.
39. Miyake, K., C. B. Underbill, J. Lasely, and P. W. Kincade. 1990. Hyaluronate can function as a cell adhesion molecule and CD44 participates in byaluronate recognition. J. Exp. Med. 172:69.
40. Murakami, S., K. Miyake, C. H. June, P. W. Kincade, and R. J. Modes. 1990. IL-5 induced a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. J. Immunol. 145: 3618.
41. Lesley. J., N. Howes, A. Perschl, and R. Hyman. 1992. Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response. J. Exp. Med. 180:383.
42. Lasley, J., and R. Hyman. 1992. CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells. Ear. J. Immunol. 22:2719.
43. Lasley, J., Q. He, K. Miyake, A. Hamann, R. Hyman, and P. W. Kincade. 1992. Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J. Exp. Med. 175:257.